UPDATE: Baird Upgrades Arrowhead Research (ARWR) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- Nvidia wins CPU business from Modal, previously exclusive to AMD and Intel
SVB Leerink Downgrades The Medicines Company (MDCO) to Market Perform
November 25, 2019 8:10 PM ESTSVB Leerink analyst Joseph Schwartz downgraded The Medicines Company (NASDAQ: MDCO) from Outperform to Market Perform with a price target of $85.00 (from $78.00).
For an analyst ratings summary and ratings history on The Medicines Company... More



